A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Keytruda, Opdivo, Tagrisso Breach 100 Billion Yen Sales Mark in FY2021: Tally
July 22, 2022
-
BUSINESS Shionogi to Steadily Promote PIII Trial for COVID Pill after Approval Setback
July 22, 2022
-
REGULATORY Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
-
REGULATORY MHLW Official Sees More “Specified Clinical Research” Data Used in Regulatory Submissions to Fill Industry-Academia Void
July 20, 2022
-
REGULATORY MHLW Eyes Expert Panel Launch This Summer for Drug Distribution and Pricing: Official
July 19, 2022
-
REGULATORY Japan Plans to Lower Minimum Age for Novavax Jab to 12
July 19, 2022
-
ORGANIZATION Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief
July 15, 2022
-
BUSINESS Pfizer Japan Files COVID-19 Vaccine for Ages 6 Months to 4 Years
July 15, 2022
-
REGULATORY Shionogi’s COVID-19 Pill Up for Expert Redeliberation on July 20
July 14, 2022
-
BUSINESS Shionogi’s Four-Day Workweek Not So Popular Yet, but Side Job Plan Gaining Traction
July 13, 2022
-
ORGANIZATION JPMA Think Tank Finds Surge in Japan-Unapproved Drugs in Areas with High Unmet Needs
July 12, 2022
-
REGULATORY After Abe’s Death, Pharma and Medical Circles Fret Shift to Austerity and Tougher Drug Pricing
July 11, 2022
-
BUSINESS As LOEs Loom, Can Mochida Roll Out Authorized Generics for Lexapro and Lialda?
July 8, 2022
-
REGULATORY All Eyes on Scope of Drugs Possibly Designated as Key Resources; Full Discussions after Upper House Poll
July 7, 2022
-
BUSINESS Lecanemab Accepted for US Review, Action Date Set for January: Eisai/Biogen
July 7, 2022
-
BUSINESS Astellas Looks to Beat Innovation Malaise through Organizational and HR Rejig
July 6, 2022
-
REGULATORY MHLW Preparing Inspection Manual after GMP Issues, Draft Due Out by March-End
July 5, 2022
-
BUSINESS Shionogi Starts Document Submission for COVID Pill in China
July 5, 2022
-
BUSINESS BMS Japan Launches New Head Office as It Looks to Spur Ideas through Casual Chats
July 5, 2022
-
BUSINESS Chugai Best-Paying Japan Pharma in FY2021, 25 Drug Makers Pay Average 8.33 Million Yen
July 4, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…